TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01097226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple extract delivering 70 mg epicatechin
Description: Delivered as a flavoured water based beverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple extract delivering 140 mg epicatechin
Description: Delivered as a flavoured water based beverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple granules delivering 70 mg epicatechin
Description: Delivered as a puree

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water delivering no epicatechin
Description: Delivered as flavoured water
Study: NCT03185624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Antibiotics
Study: NCT01699997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intranasal spray with 40 IU of OXT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal spray with placebo solution
Study: NCT03021759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active choice
Description: Statin options are framed to physicians as an active choice to prescribe or not prescribe a statin

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active choice
Description: Statin options are framed to physicians as an active choice to prescribe or not prescribe a statin

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social comparison feedback
Description: Statin prescribing rates are communicated to physicians and along with how their performance compares to their peers
Study: NCT00710333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: 10 patients undergoing surgical revision of bilateral keloids will be dosed with 500ng Juvista/100µL per cm of wound margin to one ear lobe and placebo to the other and followed up for three months after dosing to assess the local and systemic tolerability.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02517346

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up
Description: Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Follow up by telemonitoring system during 3 months
Study: NCT04089644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: closed-loop system
Description: Hypotension will be corrected by an automated system for vasopressor administration.~Fluids will be given using a goal directed strategy (EV1000 Monitor, Edwards Lifesciences, Irvine, CA, USA)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual adjustment
Description: Vasopressor agents will be manually adjusted (standard practice).~Fluids will be given using a goal directed strategy (EV1000 Monitor, Edwards Lifesciences, Irvine, CA, USA)
Study: NCT00014144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Study: NCT04441203

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CardioMems
Description: novel implantable sensor inserted into the right pulmonary artery that measures pulmonary artery pressures (PAP) in patients with HF, the CardioMEMS™ HF System
Study: NCT02325401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Escalating doses of 2000mg, 2550 mg and 3000mg. Starting 1 week prior to the initiation of chemoradiation and ending the final day of chemo or radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Dosed at 100mg/m2 on days 1, 22, and 43

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 70 Gy in 2 Gy once daily fractions of 35 fractions
Study: NCT00753324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine three-drug antiretroviral prophylaxis
Description: Women who are identified as HIV-infected will be offered routine combination antiretroviral prophylaxis starting at 28 weeks gestation (timing consistent with Zambian national guidelines for short-course ZDV). The first-line combination provided to pregnant women will be standardized following consultation with the Ministry of Health, but will likely include ZDV, lamivudine (3TC) and either NVP or lopinavir / ritonavir. In women who with moderate to severe anemia, ZDV is substituted with stavudine (d4T). In accordance with the Zambian national guidelines, any patients who are started on NVP will begin with a once daily dose for two weeks before increasing to the regular twice daily schedule
Study: NCT02011841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: rifaximin 1200 mg/day orally for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: ciprofloxacin 500 mg/day orally for 6 months
Study: NCT00058890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Under code, the study drug was started at 100 mg by mouth 3 times a day for 3 days, to be increased, if necessary and in the absence of side effects, by 300 mg every 3 days to a maximum of 2,400 mg daily in divided doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04359836

Intervention type: OTHER
Intervention: There is no intervention in this study
Description: There is no intervention in this study
Study: NCT04188041

Intervention type: OTHER
Group type: OTHER
Intervention: TB Infection ECHO
Description: A six-month virtual telementoring course regarding TB infection testing and treatment that incorporates didactics, case presentation, and discussion

Intervention type: OTHER
Group type: OTHER
Intervention: TB Infection ECHO
Description: A six-month virtual telementoring course regarding TB infection testing and treatment that incorporates didactics, case presentation, and discussion
Study: NCT00844194

Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine 60 mg QD
Description: given to (1) all patients week 2-6; (2) all responders of both arms week 7-12

Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine 60 mg QD
Description: given to (1) all patients week 2-6; (2) all responders of both arms week 7-12

Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine 30 mg QD
Description: given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)

Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine 30 mg QD
Description: given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)

Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine 90 mg QD
Description: given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD

Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine 90 mg QD
Description: given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD

Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine 60 mg QD
Description: given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down

Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine 60 mg QD
Description: given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down

Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine 120 mg QD
Description: given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated

Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine 30 mg QD
Description: given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)

Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine 30 mg QD
Description: given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)

Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine 120 mg QD
Description: given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
Study: NCT03396744

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light
Description: Placebo light (50 Lux) during 1 week and then active bright light with glasses using a dosage escalation (inter- and intra-subject) of 7.5, 10, 15, 30 and 45 min

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light
Description: Placebo light (50 Lux) during 1 week and then active bright light with glasses using a dosage escalation (inter- and intra-subject) of 7.5, 10, 15, 30 and 45 min
Study: NCT02560129

Intervention type: OTHER
Intervention: Questionnaires, Physical and Cognitive Function
Description: ICU survivors will be administered a battery of questionnaires. Measurements of physical and cognitive function will also be performed.
Study: NCT04174274

Intervention type: OTHER
Intervention: ventilator-associated pneumonia-developed group followed by mechanical ventilation
Description: compliance with ventilator-associated pneumonia prevention methods and investigating the incidence of ventilator-associated pneumonia in intensive care units

Intervention type: OTHER
Intervention: not ventilator-associated pneumonia-developed group followed by mechanical ventilation
Description: compliance with ventilator-associated pneumonia prevention methods and investigating the incidence of ventilator-associated pneumonia in intensive care units
Study: NCT01719965

Intervention type: OTHER
Intervention: Interviews and Focus Group Discussions

Intervention type: OTHER
Intervention: Interviews and Focus Group Discussions

Intervention type: OTHER
Intervention: Interviews and Focus Group Discussions

Intervention type: OTHER
Intervention: Interviews and Focus Group Discussions

Intervention type: OTHER
Intervention: Interviews and Focus Group Discussions
Study: NCT00803023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate
Description: 4.5 grams per night taken in two equally divided doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate & 6 Tablets
Description: 4.5 grams taken as a combination of liquid and 6 Placebo tablets in two equally divided doses per night

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate & 8 Tablets
Description: 6 grams taken as a combination of liquid and 8 Placebo tablets in two equally divided doses per night

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate Oral Solution (6 grams)
Description: 6 grams per night taken in two equally divided doses
Study: NCT04575779

Intervention type: DRUG
Intervention: Cyclosporin with a daily dose of 3 mg/kg/day intravenously over 2 h (short infusion) every 12 h
Description: To determine whether administering CsA at a dailydose of 3 mg/kg/day intravenously(i.v.) in 2 hrs (short infusion) twice-daily will achieve C2 blood levels of at least 800 mg/l and whether it will be feasible and safe or not.

Intervention type: DRUG
Intervention: Cyclosporin with a daily dose of 3 mg/kg/day intravenously over 2 h (short infusion) every 12 h
Description: To determine whether administering CsA at a dailydose of 3 mg/kg/day intravenously(i.v.) in 2 hrs (short infusion) twice-daily will achieve C2 blood levels of at least 800 mg/l and whether it will be feasible and safe or not.
Study: NCT04623619

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acetyl L-Carnitine
Description: Administering 2 gr of Acetyl L-Carnitine orally in addition to the standard of care therapy for 14 days
Study: NCT03404024

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: C-Cathez® Catheter
Description: Day 0 (Stage 1-Low dose VM202RY): 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-Middle dose VM202RY): 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-High dose VM202RY): 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 2-Placebo): 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl) Day 0 (Stage 2-Low dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY) Day 0 (Stage 2-High dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)
Study: NCT01542528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IBBS
Description: Combination of computer-presented brain exercises with a physical education curriculum designed to enhance sustained attention, inhibitory control and other executive capacities. Groups of 10 students incorporating the Good Behavior Game. Two-hour sessions four days a week: classroom with computers (45-60 mins) plus sports activities in the gymnasium (45-60 mins) extending over a total 15 weeks (60 sessions).
Study: NCT01462734

Intervention type: PROCEDURE
Intervention: human vitreous and blood serum sampling, PCR
Description: 1ml of human vitreous and 3ml of human blood serum
Study: NCT02760186

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Altitude Exposure
Description: Altitude Exposure
Study: NCT02591394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEP Clinic
Description: Patients will visit with STEP clinic staff (including a stroke nurse practitioner or stroke doctor) to receive personalized goals, stroke education (including diet and exercise), instructions to self-monitor using blood pressure cuff, and prescription medications Patient will be scheduled for additional clinic follow-up or be contacted for telephone follow-up for management of your blood pressure. Questionnaires will be administered to determine medication adherence and persistence (following instructions for prescribed medication), disability, depression, cognition, self-efficacy, and sleep apnea. The care plan determined by the STEP clinic will be shared with the patient's primary care provider.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients will complete questionnaires related to medical history and health behaviors prior to initial visit.~After being seen by the stroke neurologist, patients may be scheduled to return to the stroke clinic according the doctor's recommendations.~Recommendations for blood pressure and risk factor monitoring will be sent to primary care providers.
Study: NCT01910844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m² I.V. from day 1 to day 3 - total dose = 75 mg/m² every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Metronomic cyclophosphamide per os 150 mg from day 1 to day 14 - total dose 2100 mg every 3 weeks
Study: NCT04043052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological evaluation
Description: Psychological evaluation including: MINI (current diagnosis) ; HDRS ; MDQ ; GAD-7 ; PC-PTSD-5 ; Quality of Sleep (item 6 of the Pittsburgh Sleep Quality Index) ; CES-D ; BAI ; RRS-short form ; IES-R ; mYFAS2.0;

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychological evaluation
Description: Psychological evaluation including: MINI (current diagnosis) ; HDRS ; MDQ ; GAD-7 ; PC-PTSD-5 ; Quality of Sleep (item 6 of the Pittsburgh Sleep Quality Index) ; CES-D ; BAI ; RRS-short form ; IES-R ; mYFAS2.0;

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional evaluation
Description: Functional evaluation including : EQ5-D ; MFI ; LUNS ; SSQ ; Physical activity (IPAQ)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional evaluation
Description: Functional evaluation including : EQ5-D ; MFI ; LUNS ; SSQ ; Physical activity (IPAQ)
Study: NCT02239458

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Study: NCT04177693

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (EGCG)
Description: 800 mg (4 capsules) of EGCG (green tea extract), taken orally on a daily basis for up to 2 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (EGCG)
Description: 800 mg (4 capsules) of EGCG (green tea extract), taken orally on a daily basis for up to 2 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (EGCG)
Description: 800 mg (4 capsules) of EGCG (green tea extract), taken orally on a daily basis for up to 2 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate
Description: 100 mg for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 5 mg for 5 days
Study: NCT00883571

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: house advancement flap group
Description: A house flap of healthy tissue was incised to the depth of ischiorectal fat. The flap consisted of skin and subcutaneous tissue. The flap was sufficiently mobilized without undermining its fatty base containing perforating blood vessels. The flap should be loose and easily advanced into the anal canal. When the ''base'' of this house-shaped flap was advanced into the anal canal defect, it was fixed to the top of the excised area with 3/0 Vicryl sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rhomboid flap GROUP
Description: A rhomboid flap was incised in ischeorectal fossa and was mobilized without undermining of its fatty base into the anal canal so that the tip of rhomboid flap is sutured to the top of stricured area using vicryl 3/0.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Y-V anoplasty GROUP
Description: Y-V anoplastyis performed by making a v shaped incision in the perianal skin posteriorly starting from the lower end of the wound resultant from excision of scared area. A V-shaped flap is then dissected with preservation fatty base .The V flap is then advanced into the anal canal so that its tip is sutured to the top of structured area using vicryel 3/0.
Study: NCT02259530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Psychotherapeutic Intervention
Description: Evidence-based standard tools for the treatment of PTSD and comorbid khat dependence: Community Reinforcement Approach, Relapse Prevention, Narrative Exposure Therapy
Study: NCT04043052

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological assessment
Description: Biological assessment : White and red blood cells count ; platelets count ; Haemoglobin ; CRPus ; Glycaemia ; Plasmatic HbA1c ; Plasmatic LDLc ; HDLc and triglyceride ; Creatinin clearance, Transaminases.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological assessment
Description: Biological assessment : White and red blood cells count ; platelets count ; Haemoglobin ; CRPus ; Glycaemia ; Plasmatic HbA1c ; Plasmatic LDLc ; HDLc and triglyceride ; Creatinin clearance, Transaminases.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment
Description: During 3 months after inclusion, a 3 to 5 minutes daily interview will administer questions concerning mood symptoms, activities, stress experience, substance use, social relationships and medication intake, activities, social interaction, environmental conditions, experience of depressed mood, anhedonia, changes in weight, appetite, sleep, fatigue, feelings of worthlessness or inappropriate guilt, concentration or decision-making difficulty
Study: NCT00633295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMN107- NILOTINIB
Description: The dose of nilotinib will be 400 mg bid.
Study: NCT03042806

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: questionnaire
Description: all the COPD patients will be ask to complete the questionnaire
Study: NCT02731092

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: Bovine Lactoferrin 100 mg/ml dissolved in sterile water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: Bovine Lactoferrin 100 mg/ml dissolved in sterile water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: Bovine Lactoferrin 100 mg/ml dissolved in sterile water
Study: NCT03726359

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated Stereotactic Radiation Therapy
Description: Initial starting dose will be 7 Gy x5= 35 Gy delivered to the planning target volume (PTV). Radiotherapy will be delivered every other day so that the SBRT schedule is completed within 1.5-2 weeks.
Study: NCT03238001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCTclock
Description: DCTclock is a quick and non-invasive test that measures cognitive function based on a computerized algorithmic analysis of the entire drawing process and output of a well-established cognitive assessment called The Clock Drawing Test (CDT).
Study: NCT02021435

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: salt substitute
Description: Free salt substitute provided
Study: NCT00770016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxin
Description: Dosage regulation will follow the local recommendations of treatment
Study: NCT01762761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: TPO-R agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03224468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Marijuana
Description: Patients in this group can choose when, where, and how much medical marijuana to use.
Study: NCT04365036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: toripalimab 240mg, d1, intravenous drip
Study: NCT02379338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Fluortriopride
Description: All subjects will receive a \[18F\]Fluortriopride PET/CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Fluortriopride
Description: All subjects will receive a \[18F\]Fluortriopride PET/CT scan